Clinical investigators presented data showing Scios Nova Inc.'sNatrecor BNP, delivered at the two highest doses, demonstratedstatistically significant results in certain measures of cardiac functionin a Phase I/II trial.

Results from the double-blind, placebo-controlled, dose-rangingstudy with 24 patients were presented at the American HeartAssociation's 67th Scientific Sessions in Dallas. The trial involvedplacebo and bolus injections of 0.3, 1.0, 3.0 and 10.0 mcg/kg ofNatrecor, a brain natriuretic peptide, which is a naturally occurringhormone.

Kira Bacon, director of investor relations for Mountain View, Calif.-based Scios Nova, said statistical significance was seen in the 3.0and 10.0 mcg/kg doses as it related to decreases in systemic vascularresistance, pulmonary capillary wedge pressure, right arterialpressure and an increase in cardiac index without a symptomaticincrease in congestive heart failure.

"There are very interesting results, albeit early results," Bacon toldBioWorld. "This gives us the kind of information we need to pushforward into larger studies."

Scios Nova already has begun Phase II studies for Natrecor BNP.Last month the company said it was starting two 60-patient dose-ranging studies in which patients will receive multiple bolusinjections of the drug over 24 hours. Later Phase II studies willinvolve infusions.

Scios Nova (NASDAQ:SCIO) released the news after the marketclosed Tuesday. Its stock was down 50 cents Wednesday, closing at$6.25 per share. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.